Vabysmos safety profile was consistent with earlier trials, though Genentech noted that information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion has been added to the drugs label across indications
Based on TRIUMPH-4 and expected 2026 trial readouts, analysts project NDA submission in Q4 2026 or Q1 2027, FDA approval in mid-to-late 2027, and commercial launch in early 2028
Raw fluorescence values were corrected for background fluorescence, which was measured in wells without cells containing only medium, one-step assay buffer and test compound
Unexplained weight gain deserves a workup, not a fat-burner shot
Save Your Body Hormone & BioClinic 375 South 12th Street Suite 3, Tampa, FL, USA Copyright 2025 Save Your Body Hormone & BioClinic - All Rights Reserved
Bottom line : If you wanna get serious about retinoids, RP is not your ingredient (retinol or tretinoin is!)